rhinitis%20-%20nonallergic
RHINITIS - NONALLERGIC
Nonallergic rhinitis is the inflammation of the nasal lining membranes without any immunoglobulin E mediation, as documented by allergen skin testing.
Major signs and symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Symptoms can reverse spontaneously with or without treatment.

Rhinitis%20-%20nonallergic Signs and Symptoms

Definition

Rhinitis:  

  • Inflammation of the nasal lining membranes
  • Its divided into allergic rhinitis (AR) & nonallergic rhinitis (NAR) based on a basic allergological evaluations

Nonallergic Rhinitis

  • NAR is comprised by a group of diseases characterized by the presence of at least two nasal symptoms (obstruction, rhinorrhoea, sneezing, pruritus), more importantly by absence of sensitization to allergens

Signs and Symptoms

Major Signs & Symptoms:
  • Nasal itching
  • Watery rhinorrhea
  • Nasal obstruction/congestion
  • Sneezing
  • Postnasal drainage
Other Signs & Symptoms:
  • Headache
  • Conjunctival symptoms, eye pruritus
  • Impaired smell
  • Morning cough
Symptoms can reverse spontaneously w/ or without treatment
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.